A699 32.5% oncology, 17.5% auto-immune, 15% cardiovascular, 10% neurology/mental health, 5% infectious, 5% diabetes, and 15% other. Modeling techniques included discrete event simulation (12%), individual state-transition (15%) and most commonly state transition with tracking states. In most cases treatment sequencing was modeled to reflect clinical practice or clinical trial design. Other reasons included assessing where in a treatment sequence the new treatment belongs or evaluating the addition of more efficacious treatment options to the current treatment sequence. Efficacy inputs were generally based on trials that considered a single intervention and not a treatment sequence. Efficacy was commonly assumed to be the same regardless of line of therapy. Disease-related costs and utilities were mostly determined by disease status or its related events, and only seldomly by line of therapy. ConClusions: Capturing treatment sequences in economic models is important for informing reimbursement, policy and clinical decisions. Key considerations for determining how to best model sequences include: the number of treatment options, patient heterogeneity, key outcome events and event risk (time-varying or constant). A key challenge to model treatment sequences is the scarcity of the clinical data as clinical trials do not commonly study sequences.
objeCtives: To conduct budget impact analysis of neurotrophic and neuroprotective drug cerebrolysin with standard therapy compared to standard therapy only of ischemic stroke of moderate and severe degrees of severity according to the Russian healthcare system. Methods: The one year budget impact analysis was conducted. We used the pharmacoeconomic analysis method -budget impact analysis and analysis of the direct and indirect costs. For reference, we accepted the exchange rate was 1 EUR = 60,64 RUB. Results: Direct costs include the cost of pharmacotherapy cerebrolysin, the cost of medical emergencies, inpatient and outpatient -polyclinic medical care, as well as the cost of early neurorehabilitation, and indirect costs -the loss of gross domestic product as a result of disability and death, payments for sick leave and disability cost. As a result, the overall costs of standard treatment with cerebrolysin totaled 378 278 RUB (6238 EUR); while the cost to standard therapy was 457 981 RUB (7552 EUR). Reducing the direct and indirect costs was obtained in the treatment group of cerebrolysin, because of lower mortality and reduce days of hospital stay compared with the standard therapy. ConClusions: The results of budget impact analysis showed that the inclusion of cerebrolysin in standard therapy of ischemic stroke of moderate and severe degrees of severity can reduce the overall cost of the Russian health care system at 79 703 RUB (1314 EUR) per patient per year.
PRM96 a coMPaRIson of thRee suRvIval Models to estIMate the cost-effectIveness of canceR IMMunotheRaPy In the tReatMent of advanced MelanoMa
Bohensky M 1 , Gorelik A 2 , Kim H 3 , Liew D 1 1 Melbourne University, Parkville, Australia, 2 Royal Melbourne Hospital, Parkville, Australia, 3 Bristol-Myers Squibb Australia, Mulgrave, Australia objeCtives: To compare methods for extrapolating survival curves for previously-untreated patients receiving nivolumab versus ipilimumab for BRAF wildtype advanced melanoma (AM, comprising unresectable Stage III and/or Stage IV metastatic melanoma). Methods: Patient-level data from 203 patients with AM receiving nivolumab in a phase III study (nivolumab versus dacarbazine) were used to estimate hazards of progression and death. Of these, 56.2% (n= 114) progressed and 23.2% (n= 47) died during the study period. Weibull, log-logistic and a Weibull mixture cure model (MCM) were fitted to extrapolate trial data for overall survival (OS) and progression-free survival (PFS) up to a 10 year time horizon. To estimate transition probabilities for subjects receiving ipilimumab, hazard ratios were calculated by indirect comparison of nivolumab versus ipilimumab and applied to underlying survival distributions. Models were evaluated graphically, using Akaike's Information Criterion (AIC) and naive comparison of the extrapolated ipilimumab survival functions with published long-term survival data. Results: AIC scores for the Weibull, log-logistic and MCM were 336.47, 335.30 and 776.20 for OS, respectively. The equivalent AIC scores for PFS were 511.39, 479.38 and 1421.63. The estimated 3-year survival rate of patients receiving ipilimumab was 2.8%, 15.1% and 55.8% and 14.9%, 40.2% and 87.2% for patients receiving nivolumab using the Weibull, loglogistic and MCM, respectively. This compares with published data showing approximately 21% (95% CI: 17-24%) of AM patients receiving ipilimumab (3 mg/kg) survive three years. Due to the short follow-up period for this study, the MCM introduced the greatest potential for error. ConClusions: The log-logistic model provided the closest approximation to real-world ipilimumab data. The choice of parametric model exerts a large effect on predicted effectiveness and cost-effectiveness of new therapies and needs justification. Different models should be considered in sensitivity analyses to estimate their impact on ICERs.
PRM97 econoMIc and clInIcal IMPact of secondhand sMokIng In koRea
Lee J, Lee Y, Bae S Ewha Womans University, Seoul, South Korea bACkgRound: The health consequences attributed to cigarette smoking and secondhand smoke exposure have been studied in many countries. Nevertheless, the economic burden of smoking, especially focusing on secondhand smoke is rarely dealt with. objeCtives: To examine economic and health outcomes of secondhand smoking in Korea Methods: We reviewed previous studies which demonstrated the states (preclinical, MCI, mild, moderate, or severe AD). Patients' rate of progression through the health states was based on a weighted average of rates among 'slow' and 'fast' progressing patients (derived from the AD neuroimaging initiative). Each state has unique utility and expenditure impacts. This lifetime horizon model tracks AD progression, life years, quality-adjusted life years, and expenditure. ConClusions: This new framework provides a relatively simple and flexible way for users to simulate long-term AD and MCI health outcomes and assess the comparative effectiveness of strategies using a common trial endpoint.
PRM92 a coMPaRIson of dIscRete event sIMulatIon (des) veRsus MaRkov Models WIth a PRactIcal aPPlIcatIon to huMan-IMMunodefIcIency vIRus (hIv)
Gillies H Abacus International, Bicester, UK objeCtives: When conducting an economic evaluation, it is important to select an appropriate model type and provide a justification. Many analyses utilise Markov models but these are associated with a number of limitations. Discrete Event Simulation (DES) models, in which events are estimated using discrete time intervals rather than regular cycles and patients are simulated individually rather than as a cohort, can overcome many of the Markovian limitations. The aim of this study was to assess the advantages and disadvantages of DES and Markov models; utilising an application to HIV. Methods: A systematic literature review was conducted to identify modelling approaches assessing the cost-effectiveness of HIV treatments. Additionally, the use of DES models within Health Technology Assessments (HTA) was evaluated. A de novo DES was developed in Microsoft Excel® with VBA, based on assumptions and data from an existing cost-effectiveness Markov model assessing HIV treatments. Results: Of the HIV publications identified, 4% used a DES and 42% used a Markov model. Only 17% provided a discussion around their choice of model type. DES models have not yet been used in HTAs for HIV in the UK but nine were identified within other disease areas. The de novo DES and those in the published literature demonstrated a realistic modelling approach due to the discrete timing of events and accounting for patient heterogeneity. The DES is a flexible model which can accommodate future adaptations; however, it relies heavily on data requirements in order to maximise its potential benefit. ConClusions: Neither Markov models nor DES are superior; the key is to choose the most suitable model for the decision problem and provide a clear rationale. In the context of HIV, DES is likely to be a good choice of model providing sufficient data is available. 
PRM93 selectIng evIdence-Based PReventIve tReatMent thResholds By oPtIMIzIng PRefeRRed outcoMes

objeCtives:
We demonstrate an approach to select evidence-based preventive treatment thresholds by optimizing preferred outcomes illustrated with a study on preventive statin treatment based on 10-year coronary heart disease (CHD) risk predicted by the Framingham risk score (FRS). Methods: A Markov decision-analytic model was used to simulate cohorts following usual care; preventive statin treatment in high-risk (FRS≥ 20%) individuals (ATPIII guideline), or, alternatively, an explorative approach of lowering treatment threshold T from 20.0% to 0.0% with 0.5% decrements. A population-based cohort (n= 11,649) was used to recalibrate the FRS and calculate the distribution of individuals over the low (< 0.5T%), intermediate (0.5T%-T%), and high (≥ T%) risk category and corresponding observed CHD risks. Treatment complications, quality-adjusted life-years (QALYs), and Net Health Benefit (NHB) (willingness-to-pay of $50,000/QALY) were evaluated. Uncertainty was assessed through probabilistic sensitivity analysis. Furthermore, we assessed the balance between additional individuals treated and additional health benefits when incrementally lowering the threshold. Results: Over a 30-year time horizon, QALYs in men ranged from 12.679 at T= 20.0% to 12.752 at T= 0.0%, with a maximum of 12.753 at T= 1.5%. For women QALYs ranged from 13.474 at T= 20.0% to 13.587 at T= 0.0%, with a maximum of 13.589 at T= 1.5%. Lowering the threshold monotonically increased costs, whereas the incremental NHB was favorable for every T< 20%. Incrementally lowering the threshold and comparing outcomes to the former threshold, for men and women marginal health effects achieved a maximum at T= 10.0%, whereas marginal costs were highest at T= 1.0% for men and T= 2.5% for women. The marginal NHB was favorable down to T= 2.0% for men and T= 3.5% for women. ConClusions: Riskstratified prevention is increasingly recommended, while current intuition-based treatment threshold selection leaves ample room for health gain and cost-savings. Evidence-based selection, including estimation of long-term (marginal) health effects and costs, is essential, whether the goal is to maximize health outcomes or optimize cost-effectiveness.
PRM94
ModelIng tReatMent sequences In health technology assessMents
Zheng Y, Pan F, Sorensen S Evidera, Bethesda, MD, USA objeCtives: As interventions available in a therapeutic area increase, the relevant decision question in health technology assessment (HTA) expands to include identifying the optimal treatment sequences or position for a treatment in a sequence. This study reviewed economic models capturing treatment sequences published by National Institute for Health and Care Excellence (NICE). Methods: Economic models including a treatment sequence assessed by NICE were reviewed as these HTAs generally provide comprehensive detail on modeling. The rationale for modeling a sequence, modeling technique used, and approach to characterizing clinical, cost and utility impacts were evaluated. Results: Forty models were identified that considered treatment sequences in the following therapeutic areas:
